Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OHB-607 versus standard neonatal care for prevention of bronchopulmonary dysplasia in extremely premature infants
2024-515914-41-00Phase 2Authorised
- Sponsor
- Ohb Neonatology Limited
- Start
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
Phase 2, randomised, open-label trial of Premiplex in bronchopulmonary dysplasia (BPD) (2 arms), sponsored by Ohb Neonatology Limited. Primary endpoints: Incidence of severe bronchopulmonary dysplasia or death by 36 weeks postmenstrual age and Modified NICHD bronchopulmonary dysplasia severity categories. Planned start Jul 2024; status: authorised.
02
Drugs
Premiplex
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on 2024-515914-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515914-41-00.